Skip to content Skip to footer
Subscribe Now
Weekly Snapshot

PharmaShots Weekly Snapshots (May 19, 2025 – May 23, 2025)   

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilar, DigiHealth & Animal Health. Check out our full report below:   Apnimed Reports Topline P-III (SynAIRgy) Trial Data of AD109 for Obstructive Sleep Apnea (OSA) Read More: Apnimed Ionis Reveals Topline P-III (ESSENCE) Trial Data of Olezarsen for Moderate…
May 23, 2025

Read more

Petvivo Holdings & PiezoBioMembrane
News

Petvivo Holdings Collaborates with PiezoBioMembrane to Develop Functional Biomaterials

Shots:PetVivo Holdings & its subsidiary PetVivo Animal Health has entered into a master services agreement with PiezoBioMembrane to develop biocompatible biomaterial that mimics mammalian extracellular matrixAs per the deal, PetVivo & PiezoBio will co-develop a piezo-biomaterial combining ECM biomaterial & piezoelectric nanofibers to enable biologically activated healing, regeneration, & remodelling of damaged or…
May 23, 2025

Read more

Pet Pace
News

TelmyVet and PetPace Launch Quality-of-Life Consultation to Support Pets and Families in End-of-Life Care

Shots:TelmyVet & PetPace have launched the Quality-of-Life Consultation, a virtual care service to support pets & their families during end-of-life stagesService combines TelmyVet’s telemedicine platform with PetPace’s AI-powered smart collar, which tracks HRV, vital signs, mobility, & behavior to assess pain & stress. It offers a supportive space for pet parent guidance &…
May 15, 2025

Read more

Weekly Snapshot

PharmaShots Weekly Snapshots (May 05, 2025 – May 09, 2025) 

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, Biosimilar & Animal Health. Check out our full report below:   Recursion Presents Preliminary P-Ib/II (TUPELO) Trial Data of REC-4881 for Familial Adenomatous Polyposis (FAP) at DDW 2025 Read More: Recursion Chengdu Origen and Vanotech Report the First Patient Dosing in P-I (VAN-2401)…
May 9, 2025

Read more

TriviumVet
News

PBI-Gordon Companies Acquires TriviumVet, Expanding its Animal Healthcare Product Portfolio

Shots:PBI-Gordon Companies has acquired TriviumVet, incl. its product Felycin-CA1 (Sirolimus Delayed-Release Tablets), adding it to the PRN Pharmacal portfolio (PBI-Gordon’s Brand) to expand its animal healthcare product portfolioFelycin-CA1 will be available for veterinary orders by Aug 2025, with PRN Pharmacal expanding its team by hiring over 50 additional employeesFelycin-CA1 has been conditionally…
May 7, 2025

Read more

Merck Animal Health
News

Merck Animal Health’s Mometamax Single Receives the US FDA’s Approval to Treat Dogs with Otitis Externa

Shots:The US FDA has approved Mometamax Single (gentamicin, posaconazole, & mometasone furoate otic suspension) to treat otitis externa in dogs; commercially available by the summer of 2025Mometamax Single has shown favorable efficacy, with 80.5% resolution of clinical signs in dogs vs 19.6% with PBOMometamax Single is a single-dose in-clinic treatment for otitis…
May 5, 2025

Read more

Merck Animal Health & AmacaThera
News

Merck Animal Health Collaborates with AmacaThera to Develop Long-Acting Injectable Formulations for Veterinary Use

Shots:Merck Animal Health has entered into a binding evaluation & option agreement with AmacaThera to develop long-acting formulations for veterinary useCollaboration will leverage AmacaThera’s AmacaGel hydrogel platform to develop single-injection veterinary therapeutics with enhanced sustained drug deliveryAmacaGel is a fast-gelling hydrogel composed of 2 established polymers, designed to liquefy under shear force…
May 2, 2025

Read more

Vivani Medical & Okava
News

Vivani Medical & Okava Pharmaceuticals Extend Collaboration to Develop OKV-119 for Canine Cardiometabolic Diseases

Shots:Vivani Medical & Okava Pharmaceuticals have expanded their 2019 collaboration to develop OKV-119 for cardiometabolic conditions in dogs, which initially focused on catsFinancial terms of the expanded agreement remain undisclosed but incl. future milestones & royalty payments to VivaniOKV-119 (GLP-1 receptor agonists) uses Vivani’s NanoPortal tech for steady drug delivery over time from…
April 16, 2025

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]